Recent advances in structural studies of the carbonic anhydrase family: The crystal structure of human CA IX and CA XIII

Current Pharmaceutical Design

Volumn 16, Issue 29, 2010, Pages 3246-3254

  Supuran, Claudiu T ^a   di Fiore, Anna ^b   Alterio, Vincenzo ^b   Monti, Simona Maria ^b   de Simone, Giuseppina ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CNR   (Italy)

Author keywords

Carbonic anhydrase IX; Carbonic anhydrase XIII; Crystal structure; Inhibitor; Structure based drug design

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XIII; ISOENZYME; UNCLASSIFIED DRUG;

CATALYSIS; CRYSTAL STRUCTURE; CYTOSOL; DRUG DESIGN; ENZYME STRUCTURE; HUMAN; KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; X RAY CRYSTALLOGRAPHY;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; ISOENZYMES; MODELS, MOLECULAR; PROTEIN STRUCTURE, QUATERNARY;

EID: 78649882049     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793429841     Document Type: Review

References (83)

1. Supuran CT, Scozzafava A, Conway J. Eds, Carbonic anhydrase - Its inhibitors and activators. Boca Raton (FL), USA: CRC Press 2004; pp. 1-363.
2. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-81.
3. Supuran CT. Carbonic anhydrase as drug targets: general presentation. In: Supuran CT, Winum JY, Eds. Drug design of zinc-enzyme inhibitors. Hoboken, New Jersey: Wiley 2009; pp. 15-38.
4. Ferry JG. The gamma class of carbonic anhydrases. Biochim Biophys Acta 2010; 1804: 374-81.
5. Rowlett RS. Structure and catalytic mechanism of the betacarbonic anhydrases. Biochim Biophys Acta 2010; 1804: 362-73.
6. Supuran CT. Carbonic anhydrases as drug targets: an overview. Curr Top Med Chem 2007; 7: 825-33.
7. Montgomery JC, Venta PJ, Eddy RL, Fukushima YS, Shows TB, Tashian RE. Characterization of the human gene for a newly discovered carbonic anhydrase, CA VII, and its localization to chromosome 16. Genomics 1991; 11: 835-48.
8. Lehtonen JM, Shen B, Vihinen M, et al. Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J Biol Chem 2004; 279: 2719-27.
9. Whitney PL, Briggle TV. Membrane-associated carbonic anhydrase purified from bovine lung. J Biol Chem 1982; 257: 12056-9.
10. Mori K, Ogawa Y, Ebihara K, et al. Isolation and characterization of CA XIV, a novel membrane-bound carbonic anhydrase from mouse kidney. J Biol Chem 1999; 274: 15701-5.
11. Fujikawa-Adachi K, Nishimori I, Taguchi T, Onishi S. Human carbonic anhydrase XIV (CA14): cDNA cloning, mRNA expression, and mapping to chromosome 1. Genomics 1999; 61: 74-81.
12. Nagao Y, Platero JS, Waheed A, Sly WS. Human mitochondrial carbonic anhydrase: cDNA cloning, expression, subcellular localization, and mapping to chromosome 16. Proc Natl Acad Sci USA 1993; 90: 7623-27.
13. Fernley RT, Darling P, Aldred P, Wright RD, Coghlan JP, Tissue and species distribution of the secreted carbonic anhydrase isoenzyme. Biochem J 1989; 259: 91-6.
14. Parkkila S, Kaunisto K, Rajaniemi L, Kumpulainen T, Jokinen K, Rajaniemi H. Immunohistochemical localization of carbonic anhydrase isoenzymes VI, II and I in human parotid and submandibular glands. J Histochem Cytochem 1990; 38: 941-7.
15. Penschow JD, Giles ME, Coghlan JP, Fernley RT. Redistribution of carbonic anhydrase VI expression from ducts to acini during development of ovine parotid and submandibular glands. Histochem Cell Biol 1997; 107: 417-22.
16. Ogawa Y, Fernley RT, Ito R, Ijuhin N. Immunohistochemistry of carbonic anhydrase isozyme VI and II during development of the rat salivary glands. Histochem. Cell Biol 1998; 110: 81-8.
17. Ogawa Y, Toyosawa S, Inagaki T, Hong SS, Ijuhin N, Carbonic anhydrase isozyme VI in rat lacrimal gland. Histochemical 1995; 103: 387-94.
18. Karhumaa P, Leinonen J, Parkkila S, Kaunisto K, Tapanainen J, Rajaniemi H. The identification of secreted carbonic anhydrase VI as a constitutive glycoprotein of human and rat milk. Proc Natl Acad Sci USA 2001; 98: 11604-8.
19. De Simone G, Supuran CT. Antiobesity carbonic anhydrase inhibitors. Curr Top Med Chem 2007; 7: 879-84.
20. De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharm Des 2008; 14: 655-60.
21. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003; 23: 146-89.
22. Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008; 13: 383-92.
23. Andricopulo AD, Salum LB, Abraham DJ. Structure-based drug design strategies in medicinal chemistry. Curr Top Med Chem 2009; 9: 771-90.
24. KV. Structural biology, protein conformations and drug designing. Curr Protein Pept Sci 2007; 8: 376-80.
25. G. Structural biology and drug discovery. Curr Pharm Des 2006; 12: 2087-97.
26. Blundell TL, Sibanda BL, Montalvão RW, et al. Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Philos Trans R Soc Lond B Biol Sci 2006; 361: 413-23.
27. Greer J, Erickson JW, Baldwin JJ, Varney MD. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem 1994; 37: 1035-54.
28. Kannan KK, Ramanadham M, Jones TA. Structure, refinement, and function of carbonic anhydrase isozymes: refinement of human carbonic anhydrase I. Ann NY Acad Sci 1984; 429: 49-60.
29. Eriksson AE, Jones TA, Liljas A. Refined structure of human carbonic anhydrase II at 2.0 Å resolution. Proteins 1988; 4: 274-82.
30. Eriksson AE, Liljas A. Refined structure of bovine carbonic anhydrase III at 2.0 Å resolution. Proteins 1993; 16: 29-42.
31. Duda DM, Tu C, Fisher SZ, et al. Human carbonic anhydrase III: structural and kinetic study of catalysis and proton transfer. Biochemistry 2005; 44: 10046-53.
32. Stams T, Nair SK, Okuyama T, Waheed A, Sly WS, Christianson DW. Crystal structure of the secretory form of membraneassociated human carbonic anhydrase IVat 2.8 Å resolution. Proc Natl Acad Sci USA 1996; 93: 13589-94.
33. Boriack-Sjodin PA, Heck RW, Laipis PJ, Silverman DN, Christianson DW. Structure determination of murine mitochondrial carbonic anhydrase V at 2.45 Å resolution: implications for catalytic proton transfer and inhibitor design. Proc Natl Acad Sci USA 1995; 92: 10949-53.
34. Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA 2009; 106: 16233-8.
35. Whittington DA, Waheed A, Ulmasov B, et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci USA 2001; 98: 9545-50.
36. Di Fiore A, Monti SM, Hilvo M, et al. Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins 2009; 74: 164-75.
37. Whittington DA, Grubb JH, Waheed A, Shah GN, Sly WS, Christianson DW. Expression, assay, and structure of the extracellular domain of murine carbonic anhydrase XIV: implications for selective inhibition of membrane-associated isozymes. J Biol Chem 2004; 279: 7223-8.
38. Kaunisto K, Parkkila S, Tammela T, Rönnberg L, Rajaniemi H. Immunohistochemical localization of carbonic anhydrase isoenzymes in the human male reproductive tract. Histochemistry 1990; 94: 381-6.
39. Okamura N, Tajima Y, Soejima A, Masuda H, Sugita Y. Sodium bicarbonate in seminal plasma stimulates the motility of mammalian spermatozoa through direct activation of adenylate cyclase. J Biol Chem 1985; 260: 9699-705.
40. Hilvo M, Innocenti A, Monti SM, De Simone G, Supuran CT, Parkkila S. Recent advances in research on the most novel carbonic anhydrases, CA XIII and XV. Curr Pharm Des 2008; 14: 672-8.
41. Domsic JF, McKenna R. Sequestration of carbon dioxide by the hydrophobic pocket of the carbonic anhydrases. Biochim Biophys Acta 2010; 1804: 326-31.
42. Mikulski RL, Silverman DN. Proton transfer in catalysis and the role of proton shuttles in carbonic anhydrase. Biochim Biophys Acta 2010; 1804: 422-6.
43. Domsic JF, Avvaru BS, Kim CU, et al. Entrapment of carbon dioxide in the active site of carbonic anhydrase II. J Biol Chem 2008; 283: 30766-71.
44. Briganti F, Mangani S, Orioli P, Scozzafava A, Vernaglione G, Supuran CT. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. Biochemistry 1997; 36: 10384-92.
45. Lindskog S, Behravan G, Engstrand C, et al. Carbonic anhydrases from biochemistry and genetics to physiology and clinical medicine. In: Botré F, Gros G, Storey BT, Eds. Weinheim: Verlag Chemie 1991; pp. 1-13.
46. Pastorek J, Pastoreková S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994; 9: 2877-88.
47. Opavský R, Pastoreková S, Zelnik V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996; 33: 480-7.
48. Pastoreková S, Barathova M, Kopacek J, Pastorek J. Carbonic anhydrase inhibitors targeting cancer: therapeutic, immunologic, and diagnostic tools targeting isoforms IX and XI. In: Supuran CT, Winum JY, Eds. Drug design of zinc-enzyme inhibitors. Hoboken, New Jersey: Wiley 2009; pp. 193-222.
49. Hilvo M, Baranauskiene L, Salzano AM, et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 2008; 283: 27799-809.
50. Pastoreková S, Pastorek J. Cancer-related carbonic anhydrase isozymes and their inhibition. In: Supuran CT, Scozzafava A, Conway J, Eds. Carbonic anhydrase: its inhibitors and activators. Boca Raton, FL: CRC Press 2004; pp. 255-81.
51. Kaluz S, Kaluzová M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta 2009; 1795: 162-72.
52. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075-83.
53. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
54. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
55. Gut MO, Parkkila S, Vernerová Z, et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 2002; 123: 1889-903.
56. Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 2008; 14: 685-98.
57. Brahimi-Horn MC, Pouysségur J. Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem 2007; 43: 165-78.
58. Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumorassociated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005; 48: 4834-41.
59. Švastová E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004; 577: 439-45.
60. Swietach P, Wigfield S, Cobden P, Supuran CT, Harris AL, Vaughan-Jones RD. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem 2008; 283: 20473-83.
61. Závada J, Závadová Z, Pastorek J, Biesová Z, Jezek J, Velek J. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 2000; 82: 1808-13.
62. Zavadova Z, Zavada J. Carbonic anhydrase IX (CA IX) mediates tumor cell interactions with microenvironment. Oncol Rep 2005; 13: 977-82.
63. [63] Svastová E, Zilka N, Zat'ovicová M, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res 2003; 290: 332-45.
64. Beavon IR. Regulation of E-cadherin: does hypoxia initiate the metastatic cascade? Mol Pathol 1999; 52: 179-88.
65. Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 2005; 18: 2935-47.
66. Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with anions. J Enz Inhib Med Chem 2003; 18: 403-6.
67. Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors. Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2003; 13: 1005-9.
68. Innocenti A, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Interactions of phenols with the 12 catalytically active mammalian isoforms (CA I - XIV). Bioorg Med Chem Lett 2008; 18: 1583-7.
69. Maresca A, Temperini C, Vu H, Pham et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009; 131: 3057-62.
70. De Simone G, Supuran CT. Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta 2010; 1804: 404-9.
71. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-43.
72. Pastorekova S, Casini A, Scozzafava A, Vullo D, Pastorek J, Supuran CT. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004; 14: 869-73.
73. Supuran CT, Scozzafava A, Ilies MA, Briganti F. Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating 2,4,6- trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-impermeability and in vivo selectivity for the membrane-bound (CA IV) versus the cytosolic (CA I and CA II) isozymes. J Enzyme Inhib 2000; 15: 381-401.
74. Scozzafava A, Briganti F, Ilies MA, Supuran CT. Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. J Med Chem 2000; 43: 292-300.
75. Supuran CT, Manole G, Dinculescu A, et al. Carbonic anhydrase inhibitors. V: Pyrylium salts in the synthesis of isozyme-specific inhibitors. J Pharm Sci 1992; 81: 716-9.
76. Casey JR, Morgan PE, Vullo D, Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumorassociated isozyme IX. J Med Chem 2004; 47: 2337-47.
77. Innocenti A, Scozzafava A, Parkkila S, Puccetti L, De Simone G, Supuran CT. Investigations of the esterase, phosphatase and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II and XIII with 4-nitrophenyl esters as substrates. Bioorg Med Chem Lett 2008; 18: 2267-71.
78. Maresca A, Temperini C, Pochet L, Masereel B, Scozzafava A, Supuran CT. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010; 53: 335-44.
79. Dubois L, Lieuwes NG, Maresca A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)- oxygenated cells in a xenograft tumour model. Radiother Oncol 2009; 92: 423-8
80. Akurathi V, Dubois L, Lieuwes NG, et al. Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. Nuclear Med Biol 2010; in press
81. Hilvo M, Innocenti A, Monti SM, De SG, Supuran CT, Parkkila S. Recent advances in research on the most novel carbonic anhydrases, CA XIII and XV. Curr Pharm Des 2008; 14(7): 672-678.
82. Supuran CT. Carbonic anhydrases--an overview. Curr Pharm Des 2008; 14(7): 603-614.
83. Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase activation and the drug design. Curr Pharm Des 2008; 14(7): 708-715.